De-novo calcineurin-inhibitor-free immunosuppression with sirolimus and mycophenolate mofetil after heart transplantation: 5-year results

Current Opinion in Organ Transplantation

Volumn 16, Issue 5, 2011, Pages 522-528

  Meiser, Bruno ^a   Buchholz, Stefan ^a   Kaczmarek, Ingo ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Calcineurin inhibitor free immunosuppression; heart transplantation; sirolimus

Indexed keywords

CHOLESTEROL; CREATININE; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; SULFAMETHOXAZOLE; THYMOCYTE ANTIBODY; TRIMETHOPRIM; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ANEMIA; BLOOD SAMPLING; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CLINICAL PROTOCOL; CONGESTIVE CARDIOMYOPATHY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; EDEMA; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART GRAFT; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; ISCHEMIC CARDIOMYOPATHY; LONG TERM CARE; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PLEURA EFFUSION; PNEUMOCYSTIS; PNEUMOCYSTOSIS; POSTOPERATIVE PERIOD; PROGNOSIS; REVIEW; THROMBOSIS; TREATMENT DURATION; WOUND HEALING IMPAIRMENT;

CALCINEURIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE CARE; RETROSPECTIVE STUDIES; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 81155162619     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32834aa2e1     Document Type: Review

References (14)

1. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940. (Pubitemid 37064766)
2. Meiser BM, Groetzner J, Kaczmarek I, et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation 2004; 78:591-598. (Pubitemid 39097107)
3. Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: an update. Drugs Today (Barc) 2009; 45:521-532; Review.
4. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110:2694-2700. (Pubitemid 39453021)
5. Eisen HJ, Tuzcu EM, Dorent R, et al., RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349:847-858. (Pubitemid 37025404)
6. Groetzner J, Kaczmarek I, Schulz U, et al., VENINAHTx-Investigators. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation 2009; 87:726-733.
7. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004; 77:568-574. (Pubitemid 38282814)
8. Meiser B, Reichart B, Adamidis I, et al. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 2005; 5 (4 Pt 1):827-831. (Pubitemid 40461294)
9. Meiser B, Kaczmarek I, Mueller M, et al. Low-dose tacrolimus/sirolimus and steroid withdrawal in heart recipients is highly efficacious. J Heart Lung Transplant 2007; 26:598-603. (Pubitemid 46818048)
10. Kaczmarek I, Ertl B, Schmauss D, et al. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant 2006; 25:550-556.
11. Kobashigawa JA, Miller LW, Russell SD, et al., Study Investigators. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6:1377-1386. (Pubitemid 44030320)
12. Lehmkuhl HB, Arizon J, Viganò M, et al., 2411 Study Investigators. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 2009; 88:115-122.
13. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report-2010. J Heart Lung Transplant 2010; 29:1089-1103.
14. Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments [review]. Circulation 2008; 117:2131-2141. (Pubitemid 351596195)